Objective: To characterize the influence of body mass index (BMI), body composition, hormonal factors and disease duration on bone metabolism markers in anorexia nervosa (AN) patients. Design: Case-control study with 51 AN patients and 51 controls matched for age, sex and body height. Assessment of anthropometric and bioimpedance data, and of biochemical serum parameters and of oral contraceptives use. Results: Patients had a lower BMI, lower fat mass, lower fat-free mass and lower muscle mass (MM) compared to the controls (all P values o0.001). Moreover, serum levels of osteocalcin (bone formation marker) were lower while serum C-telopeptide concentrations (CTx; bone resorption marker) and the CTx/osteocalcin ratio (an index reflecting the balance of bone remodeling) were higher in the AN patients compared to the controls (Po0.01-0.001). In addition, patients had enhanced serum calcium and cortisol levels and reduced serum levels of thyroid hormones, insulin, and leptin (P values o0.05-0.001). Mean disease duration was 91713 months. In a multiple regression analysis, BMI (Po0.0001), MM (Po0.005) and duration of the disease (Po0.005) were independent predictors of the CTx/osteocalcin ratio in the AN patients. There was a nonlinear association between BMI and the CTx/osteocalcin ratio of r ¼ À0.72 (Po0.001) in the AN patients, but only a weak relation of r ¼ À0.27 (Po0.05) between these parameters in the control subjects. Use of oral contraceptives had no effect on the CTx/ osteocalcin ratio, neither in AN patients nor in controls. Conclusions: Data indicate an uncoupling of bone formation and bone resorption in AN, which is primarily the result of a low BMI and influenced by the duration of the disease.
Introduction
Anorexia nervosa (AN) is an eating disorder primarily affecting adolescent females and premenopausal women. The prevalence rate is 0.2-1.0% in Western countries (Hsu, 1996; Wakeling, 1996) . Severe osteopenia and clinical fractures are frequent complications (Biller et al, 1989; LaBan et al, 1995; Maugars et al, 1996) . The pathogenesis of osteoporosis in AN, however, has not been completely characterized. Nutritional factors such as low body mass index (BMI) (Bachrach et al, 1990) and hormonal factors such as reduced sex hormone levels (Biller et al, 1989) , and increased levels of glucocorticoids (Biller et al, 1989 ) may contribute to the low bone mineral density of AN patients. Moreover, some prospective short-term studies indicate an increased bone formation after weight gain (Stefanis et al, 1998; Heer et al, 2002) .
Several biochemical serum parameters of bone metabolism such as osteocalcin and C-telopeptide (CTx) have been established as markers of osteoblastic and osteoclastic activity, respectively (Looker et al, 2000) . It has been demonstrated in various investigations that bone metabolism markers are affected by mechanical forces, as well as by nutritional and hormonal factors (Scheld et al, 2001; Zikan et al, 2001; Zittermann et al, 2002) . Therefore, the measurement of bone formation and resorption markers can be used as a reliable tool to investigate the association between bone metabolism and AN-related pathological alterations.
Some earlier studies have demonstrated reduced osteocalcin and enhanced CTx levels in AN patients (Caillot-Augusseau et al, 2000; Hotta et al, 2000) . These previous studies also indicated that the low BMI of AN patients might be a risk factor for disturbed bone turnover. Investigations were, however, performed only in Asian women or were restricted to a very small number of subjects and did not assess hormonal factors.
In addition, little is known about the influence of disease duration on bone turnover in AN. Larger trials are, thus, necessary to establish the relative importance of a low BMI for the impaired bone metabolism observed in AN patients. We therefore performed a case-control study with 102 female volunteers to characterize the influence of BMI, body composition, hormonal factors and disease duration on markers of bone metabolism in AN patients.
Materials and methods

Subjects
We studied 51 women with AN and 51 healthy controls. Patients were recruited at three different German clinics for psychosomatic medicine. They were all inpatients and were all investigated before weight restoration, in the first days of their hospital stay.
The AN patients were 15.6-54.9 y of age (mean age 24 y). All met DSM-IV criteria, with duration of disease ranging from 7 to 502 months (mean 91 months). Only AN patients with a BMI o17.5 kg/m 2 were included. In all, 28 of the patients had restricting AN (R-AN), and the remaining 23 had binge-eating/purging AN (B-AN). Out of the 51 patients, 21 were taking oral contraceptives (OC). In all, 30 patients had secondary amenorrhea, whereby four of these patients took OC. A total of 20 patients had their menstruation during the last 4 weeks, whereby 17 of these patients took OC. In one case, data of menstruation and OC intake are missing. Control subjects were recruited by public local advertisements. A matched pairs design was used with comparable age (73 y) and body height (74 cm) of patients and controls. Only subjects with a BMI between 20 and 25 kg/m 2 and with no history of eating disorders or obesity were included as controls. None of the controls had secondary amenorrhea, and with the exception of OC use (n ¼ 26), none was on any medication. The study protocol had been approved by the local Ethics committee, and informed written consent was given by all subjects.
Study procedures
All study measurements were performed in the fasting state. Blood specimens were collected from the antecubital vein into serum monovettes and into EDTA-coated tubes in a sitting position. In the control subjects blood sampling was performed during the follicular phase between cycle days 5 and 12. Specimen aliquots were frozen consecutively and stored at À20 or À801C (leptin assay), until analysis. Body mass was measured (shorts, cotton shirt) with a precision of 50 g. Body composition was measured by bioimpedance analysis (BIA) at 50 kHz using a Multi Frequency Analyzer (Data Input GmbH, Hofheim, Germany). Briefly, a tetrapolar electrode placement was used, with electrodes placed on the dorsal surfaces of the right hand and foot. Electrodes were placed at the distal metacarpals and metatarsals, respectively, and between the distal prominences of the radius and the ulna at the wrist, and the medial and lateral malleoli at the ankle. Skinfold thickness was measured at the triceps, subscapular and suprailiacal areas using a precision calliper with a constant pressure of 10 g/mm 2 . The measuring range of the device was between 0 and 60 mm with a precision of 0.2 mm. Arm circumference was measured with a flexible centimeter measure to the nearest 0.1 cm. All bioimpedance and anthropometric measurements were performed by the same observer.
Biochemical analyses
Serum Ca, phosphorus, albumin, glucose, insulin, cortisol, free triiodothyronine (T 3 ), free thyroxin (T 4 ) and basal thyroid stimulating hormone (TSH) were analyzed using routine laboratory methods. Plasma leptin levels were measured using an ELISA kit supplied by Diagnostic Systems Laboratories, Inc. (Webster, TX, USA). Serum mid osteocalcin (bone formation marker), and serum CTx levels (bone resorption marker) and intact parathyroid hormone (PTH) were measured by means of ELISA assays using commercial test kits supplied by Osteometer BioTech (Osteocalcin, CTx; Herlev, Denmark), and by DRG Diagnostics (PTH; Marburg, Germany). Serum 25-hydroxyvitamin D (25OHD) was analysed using a 125 I-labeled RIA test kit supplied by Diasorin (Stillwater, MN, USA). The intra-assay coefficients of variation (CVs) of all ELISA and RIA kits were below 7%, and all interassay CVs were below 9%.
Calculations
The raw data of the bioimpedance measurements were used to calculate (i) total body water according to the formula of Kushner and Schoeller (1986) , (ii) fat-free mass (FFM) according to the formula TBW/0.732, and (iii) body fat from the difference between body weight and FFM. The raw data of triceps, subscapular and suprailiacal measurements were used to calculate fat mass (in kg) according to the formulae of Johnsen (1990) for adults and for females aged 15-17 y, respectively. Arm muscle area (AMA) and total muscle mass (MM) were derived using standard formulas. AMA was corrected for bone area by substracting 6.5 cm 2 from the calculated area. Total body MM was then calculated by the formula (Heymsfield et al, 1982) :
MMðkgÞ ¼ ðht; cm 2 Þð0:0264 þ 0:0029Âcorrected AMAÞ Body mass index (BMI) was calculated by the ratio of body mass (kg) to squared body height (in meter). Moreover, based on the BIA measurements, a body fat mass index (BFMI) and a body FFM index (BFFMI) were calculated according to the formulas: BFMI ¼ fat mass (kg)/squared body height (in meters); BFFMI ¼ FFM (kg)/squared body height (in meters). The formula of Heymsfield et al (1982) was used to calculate total body MM (BMMI) according to the equation: BMMI ¼ MM (kg)/ squared body height (in meters). The ratio of serum CTx/osteocalcin was used as index of the balance of bone remodeling (Hotta et al, 1998) .
Statistics
Statistical analyses were performed with the Statistical Package for the Social Sciences (SPSS/version 10, Chicago, IL, USA). For comparative evaluations, the two-tailed Student's t-test (normal distributed data) and the Wilcoxon test were used. Normal distribution of the data was tested by the Kolmogorov-Smirnov test. The Spearman rank sum correlation coefficient was used to assess inter-relationships between variables. A stepwise multiple regression analysis and nonlinear regression analyses were performed to assess the effect of independent variables on the CTx/osteocalcin ratio. P values below 0.05 (two-tailed) were considered as significant. Data are presented as means7s.e.m.
Results
Clinical and anthropometric data
The mean duration of illness in the AN patients was 91.1713.2 months. The patients' average weight loss was 25.9% of their premorbid weight. Comparisons of clinical and anthropometric data between patients and controls are summarized in Table 1 . The AN patients had significantly lower weight and BMI than controls. In the AN group, fat mass, measured either by anthropometric method or by BIA was substantially reduced. AMA, MM, FFM and basis metabolic rate were also significantly lower in AN subjects. BMI, anthropometric and BIA measurements did not differ between the subgroups of R-AN and B-AN patients (data not shown).
Biochemical data TSH levels were comparable in patients and controls, while the patients had reduced free T 3 and free T 4 levels. Moreover, insulin and glucose levels, and the insulin/glucose ratio were lower in the AN patients than in the controls (Table 1) . Cortisol concentrations were slightly higher, while leptin levels were markedly reduced in the AN patients compared to the controls. Serum phosphorus, PTH and 25OHD levels did not differ between study groups. Osteocalcin concentrations were, however, significantly lower, and serum calcium and CTx levels significantly higher in patients compared to controls. Therefore, the CTx/ osteocalcin ratio was markedly enhanced in the patients compared to controls.
In the AN patients, OC use was associated with reduced concentrations of CTx and osteocalcin levels in comparison to nonusers (Table 2) . However, OC use did not influence the CTx/osteocalcin ratio, neither in AN patients nor in the controls. Moreover, parameters of calcium metabolism did not differ in OC users and nonusers (data not shown).
Biochemical parameters of bone turnover were comparable in the subgroups of R-AN and B-AN patients (data not shown). 
Anorexia nervosa and bone turnover T Weinbrenner et al
Correlations
In the AN patients, the CTx/osteocalcin ratio was correlated with BMI, and with several anthropometric and BIA measurements (Table 3) . Moreover, the percent of weight loss per month of the AN patients was related to the CTx/ osteocalcin ratio (r ¼ 0.60; Po0.001), while the duration of the disease was inversely associated with the CTx/osteocalcin ratio (r ¼ À0.49; Po0.001).
Stepwise multiple regression analyses including age, BMI, duration of illness (only in AN patients), body fat (skinfolds), FFM (BIA), MM (circumferences), cortisol and free T 4 as independent variables were performed to assess independent variables of the CTx/osteocalcin ratio in the AN patients and the controls. According to previous results that a quadratic equation can best explain the relation between BMI and bone turnover markers (Caillot-Augusseau et al, 2000) , we performed a square root transformation of the data for statistical analysis. The CTx/ osteocalcin ratio was only related to BMI (r ¼ 0.56; Po0.0001) and to FFM (Po0.05) (multiple r ¼ 0.61; Po0.0001). No stronger association with the CTx/osteocalcin ratio was obtained when BFMI, BFFMI or BMMI entered the regression analysis as independent variables instead of BMI (data not shown).
If the data of the AN patients were analyzed separately, the CTx/osteocalcin ratio was related to BMI (r ¼ 0.53; . Non-linear association between body mass index (BMI) and the C-telopeptide/osteoclacin ratio in patients with anorexia nervosa (Fig.1a: r ¼ À0.72; Po0.001) and in control subjects, (Fig.1b: r ¼ À0.27; Po0.05). (a) C-telopeptide/osteocalcin ratio ¼ 33579À4072.3* BMI þ 124.8*(BMI) 2 , (b) C-telopeptide/osteocalcin ratio ¼ À3480 þ 339.7* BMI À 7.81* (BMI).
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Anorexia nervosa and bone turnover T Weinbrenner et al Po0.0001), MM (Po0.01) (multiple r ¼ 0.60; Po0.0001) and duration of illness (Po0.01) (multiple r ¼ 0.68; Po0.001). None of the transformed anthropometric or biochemical parameters were independent predictors of the CTx/osteocalcin in the control subjects (all P values 40.05). In the AN patients, the association between BMI and bone turnover could best be described by a nonlinear regression analysis (Figure 1a ). In the control subjects, this equation resulted only in a weak association between BMI and bone turnover (Figure 1b) . If a CTx/osteocalcin ratio of o300 pmol/mg was used as cutoff value, 45 out of the 51 controls, while only 14 out of the 51 subjects of the AN group, had values below this threshold (Figure 1a and b) . Moreover, 11 out of these 14 AN patients with relatively low CTx/osteocalcin ratios had a BMI above 16.5 kg/m 2 . Thus, the majority of AN patients with a BMI below 16.5 kg/m 2 had relatively high levels of bone resorption in comparison to bone formation. Two of the remaining three AN patients with a low CTx/osteocalcin ratio had BMIs of 15.6 and 16.2 kg/m 2 , which were still above the mean BMI value of the AN patients (Table 1) .
Discussion
The present study has demonstrated an approximately fourfold higher CTx/osteocalcin ratio in AN patients compared to healthy age-matched controls, indicating a marked uncoupling of bone formation and resorption processes (Hotta et al, 1998) . BMI was a strong predictor of the aforementioned alterations in bone turnover. The comparable changes in BMI, body composition and bone turnover in R-AN and B-AN patients (Results section) support our assumption that the low BMI is the most important predictor of a disturbed bone turnover in AN. Our data are in gross agreement with an earlier prospective study of CaillotAugusseau et al (2000) . These investigators found a nonlinear association between BMI and the CTx/osteocalcin ratio in a small group of nine AN patients and 10 controls. Our data (Figure 1a ) also confirm some earlier results indicating that bone turnover is markedly disturbed when the BMI falls below 17.5 kg/m 2 (Zipfel et al, 2001) or 16.5 kg/m 2 (Hotta et al, 2000) . Since the assessment of BMI is easy to perform in AN patients during routine clinical investigations, this parameter may give a first estimation of the degree of disturbed bone turnover in AN. According to the Utah paradigma of skeletal physiology, MM is the most important mechanical force on bone (Schiessl et al, 1998) . A close association exists between muscle and bone mass (Doyle et al, 1970; Ferretti et al, 1998; Wang et al, 1999) . Our data showing reduced FFM and MM in parallel with a disturbed bone turnover in the AN patients compared to the control subjects (Table 1) are in agreement with the findings of Schiessl et al (1998) . The fact that there was a close association between body mass, and FFM and MM in our study groups (Table 3 ) may explain why BFFMI and BMMI were not superior in predicting bone turnover compared to BMI (Results section). It may also be that the measurements of FFM and MM, which had been used to calculate BFFMI and BMMI, were not precise enough to obtain a stronger association with bone turnover compared to BMI. It should also be pointed out that these measurements are based on equations developed exclusively from populations of healthy female subjects (Kushner & Schoeller, 1986) or occasionally including a small number of AN patients (Heymsfield et al, 1982) . Thus, the equations used for body composition measurements are not well validated for AN patients.
Since the AN patients had lost approximately 26% of their premorbid body mass (Results section), the low concentrations of the bone formation marker osteocalcin and the high concentration of the bone resorption marker CTx are obviously the result of an adaptation process of the human body to achieve a new equilibrium between muscle and bone mass. Nevertheless, it is a surprising finding that such an uncoupling of bone turnover persists even after a mean duration of illness of 91 months. There is, however, some recently published evidence that bone breakdown follows muscle degradation with a lag time of several months (Fox et al, 2000; Scheld et al, 2001) . Moreover, prospective studies in AN patients lasting 25 months have failed to demonstrate a beneficial effect of weight gain on bone mineral density (Rigotti et al, 1984) supporting the hypothesis of a slow response of bone metabolism to changes in muscle metabolism. Since it may take 6-10 y of recovery from AN to achieve a bone mineral density comparable with that of healthy women of similar age (Valla et al, 2000) , we hypothesize that it may also take a similar time period to loose bone. Our data suggest that the AN subjects of our study were still in a dynamic phase of bone loss. This assumption is further supported by the higher fasting serum calcium levels of the patients compared to the controls (Table 1) indicating calcium release from bone (Nordin et al, 1987) . Moreover, the inverse association between the duration of illness and the CTx/osteocalcin ratio in the AN patients (Results section) indicates that a new equilibrium between muscle and bone metabolism may only be achieved if patients are suffering from AN for a very long time. Our data indicate that a rapid nutritional intervention after diagnosis of AN is mandatory to minimize the onset of excessive bone loss.
There has been some debate regarding the effect of either endogenous sex hormone production or of OC administration on bone health in AN patients (Grinspoon et al, 1999; Munoz et al, 2002) . Although in our study OC intake of AN patients was associated with lower serum CTx levels in comparison to AN patients who did not use OC, osteocalcin levels were also lower and the balance of bone remodeling did not differ between the two subgroups (Table 2) . These results indicate that in the AN patients OC intake had no net effect on bone accretion. The presented data are in agreement with the study of Munoz et al (2002) demonstrating that OC administration cannot prevent progressive osteopenia in young women with AN.
It is well known that high circulating glucocorticoid levels lead to severe impairment of bone mass and turnover (Di Somma et al, 2002) . The difference in serum cortisol levels between AN patients and controls was, however, rather small (Table 1 ) and serum cortisol levels had no significant independent effect on bone turnover (Results section). We therefore assume that the slightly higher level of circulating cortisol concentration of the AN patients compared to the controls was not a major contributing factor for the disturbed bone turnover.
In summary, we conclude that a disturbed bone turnover in AN is primarily the result of a low BMI. Moreover, the duration of illness seems to influence bone turnover processes in AN patients.
